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Large artery atherosclerotic stroke (LAS) shows substantial heri-
tability not explained by previous genome-wide association
studies. Here, we explore the role of coding variation in LAS by
analyzing variants on the HumanExome BeadChip in a total of
3,127 cases and 9,778 controls from Europe, Australia, and South
Asia. We report on a nonsynonymous single-nucleotide variant in
serpin family A member 1 (SERPINA1) encoding alpha-1 antitrypsin
[AAT; p.V213A; P = 5.99E-9, odds ratio (OR) = 1.22] and confirm
histone deacetylase 9 (HDAC9) as a major risk gene for LAS with an
association in the 3′-UTR (rs2023938; P = 7.76E-7, OR = 1.28). Using
quantitative microscale thermophoresis, we show that M1 (A213)
exhibits an almost twofold lower dissociation constant with its
primary target human neutrophil elastase (NE) in lipoprotein-con-
taining plasma, but not in lipid-free plasma. Hydrogen/deuterium
exchange combined with mass spectrometry further revealed a
significant difference in the global flexibility of the two variants.
The observed stronger interaction with lipoproteins in plasma and
reduced global flexibility of the Val-213 variant most likely improve
its local availability and reduce the extent of proteolytic inactivation
by other proteases in atherosclerotic plaques. Our results indicate
that the interplay between AAT, NE, and lipoprotein particles is
modulated by the gate region around position 213 in AAT, far away
from the unaltered reactive center loop (357–360). Collectively, our
findings point to a functionally relevant balance between lipopro-
teins, proteases, and AAT in atherosclerosis.
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Stroke is the leading cause of long-term disability and thesecond most common cause of death worldwide (1, 2). About
a quarter of ischemic stroke cases are caused by large artery ath-
erosclerotic stroke (LAS) (3, 4). Atherosclerosis is a chronic in-
flammatory condition that involves a number of well-characterized
steps. Initial stages include the deposition of lipids in vascular en-
dothelial cells, whereas more advanced stages are characterized by
fibrotic changes with formation of a fibrotic cap and, eventually,
plaque rupture (5). LAS exhibits the highest heritability of all stroke
subtypes, with estimates ranging from 40.3 to 66.6% (6, 7). This fact
is reflected by recent genome-wide association studies that found
common variants for LAS at multiple genomic loci (8–10). The lead
SNPs from these regions all reside within intergenic (4, 7, 11) or
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intronic (12) regions, and most of them are situated within a reg-
ulatory sequence marked by DNase I hypersensitivity sites.
Whole-exome (13) and whole-genome (14) sequencing efforts
have identified multiple common, low-frequency, and rare variants
that have not yet been examined for association with LAS. Con-
ceivably, these variants might account for some of the missing
heritability of LAS. To search for novel variants and genes impli-
cated in atherosclerotic stroke, we assembled the largest cohort of
LAS cases to date (3,127 cases and 9,778 controls from Germany,
the United Kingdom, Australia, and Pakistan).
In the current study, we found two exome-wide significant
variants, one in the established LAS risk gene histone deacetylase
9 (HDAC9) and one in serpin family A member 1 (SERPINA1).
The main target of the inhibitor alpha-1 antitrypsin (AAT),
encoded by SERPINA1, is neutrophil elastase (NE). AAT and NE
are both involved in inflammation, and an imbalance between
AAT and NE has previously been discussed as a possible mech-
anism in atherosclerotic plaque and aneurysm formation (15–18).
The rate-determining step of the inhibitory reaction between
ATT and NE is the reversible formation of a noncovalent
docking intermediate (encounter complex), which subsequently
progresses to the covalent tetrahedral complex (16, 19, 20). The
common M1 variants of AAT, the minor A213 allele and the
prevailing V213 allele (rs6647), have previously been charac-
terized as normal, functionally equivalent plasma isoforms (20)
with very similar plasma levels and association rate constants for
the purified isoforms (16, 19, 20). However, adjacent to the loop
containing residue 213 is a hydrophobic groove (16), which, to-
gether with the polymorphic side chain, may differentially in-
teract with endogenous hydrophobic components of plasma. In
this study, we functionally characterized the interaction between
AAT and NE in human plasma using microscale thermophoresis,
and provide evidence for differential behavior of the two major
M1(V213) and M1(A213) alleles toward lipoproteins.
Results
Common Variants in SERPINA1 and HDAC9 Associate with LAS.
Characteristics of the case and control samples, including de-
tails on quality control (QC), are presented in Figs. S1 and S2,
Table S1, and SI Materials and Methods. The overall strategy for
the transethnic, exome-wide association study is shown in Fig. 1.
We found two common variants to be associated with LAS on an
exome-wide level (P < 1.88E-6 with Bonferroni correction for all
common variants studied; Fig. 2 A–C and Table 1). The first
variant, exm1124208 (rs6647) in SERPINA1, encoding M1(A213) in
AAT showed a minor allele frequency (MAF) of 17.8% in
Caucasian controls and 17.1% in South Asian controls [odds
ratio (OR) 95% confidence interval [CI_95] = 1.22 [1.13–1.31],
P = 5.99E-9 in the transethnic meta-analysis] (Fig. 2 D and E).
PolyPhen2 (score = 0.0), PROVEAN (score = 1.11), and SIFT
(score = 0.54) predict this variant to be likely benign and toler-
ated. The association between LAS and rs6647 remained sig-
nificant (P = 7.01E-9) when removing carriers of the low-
frequency Z and S alleles (98 cases and 262 controls) that have
previously been shown to be associated with lower plasma levels
of AAT. The second variant, rs2023938 in HDAC9 (MAF =
9.1% and 10.8% in Caucasians and South Asian controls, re-
spectively; OR [CI_95] = 1.28 [1.16–1.40, P = 7.76E-7]), is in the
3′-UTR of HDAC9 and in high linkage disequilibrium (LD) with
previously published risk variants for LAS in the 3′ region of
HDAC9 [rs11984041 (11): r2 = 1; rs2107595 (4): r2 = 0.53].
1,463 German cases 
2,892 German controls 
Trans-ethnic meta-analysis
376 South Asian cases / 978 South Asian controls   
Final results for 
26,543 common SNPs + 66,229 low frequency/rare SNPs 
1,288 UK/Australian cases 
5,908 UK/Australian controls
Fig. 1. Flow chart of the exome chip analysis. Samples from Germany, the
United Kingdom, and Australia were pooled with samples from South Asia
for the transethnic metaanalysis.
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Fig. 2. Main association results. Shown are the re-
sults for common (A, MAF > 5%), low-frequency (B,
1% < MAF < 5%), and rare (C, MAF < 1%) variants.
Genomic position is plotted on the x axis, and the
−log10 of the P value is displayed on the y axis. The
threshold for exome-wide significance after Bonfer-
roni correction for the number of variants studied is
displayed as a dashed red line. (D) LocusZoom plot
[−log10 (p-value)] for the SERPINA1 region and LAS.
Shown is the region for the top signal ± 500 kb.
Common, low-frequency, and rare variants are dis-
played as filled circles (●), squares (■), and diamonds
(♦), respectively. Blue peaks represent estimated re-
combination rates. (E) Forest plot of associations
with rs6647 in individual samples and in the resulting
fixed-effects metaanalysis. Sample sizes are reflected
by the size of each square. Gray bars show the
[CI_95] of the point estimate.
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Among 14 variants meeting the criterion of suggestive asso-
ciation (P < 1E-4), three are situated within known risk loci for
atherosclerotic phenotypes or risk factors for atherosclerosis
(Table 1). MMP12 (21) and CYP17A1 (22) are associated
with LAS and coronary artery disease, respectively, whereas
C10orf32-AS3MT (23, 24) is an established risk locus for hy-
pertension. None of the low-frequency (MAF < 5%) and rare
(MAF < 1%) variants reached exome-wide significance (Fig. 2 B
and C). Gene-based tests revealed no exome-wide significant
signals (Table S2).
M1(A213) and Atherosclerotic Plaque Characteristics in Advanced
Stages of Disease. To explore associations between the M1
(A213) variant and histological characteristics of atherosclerotic
plaques, we analyzed 1,414 carotid endarterectomy samples
from patients with advanced atherosclerotic lesions assembled
through the Athero-Express study. The M1(A213) variant was
nominally associated with a lower macrophage content (P = 0.03,
beta = −0.19, SE = 0.09). However, when controlling for the as-
sessment of multiple plaque characteristics, including plaque hem-
orrhage, collagen content, and smooth muscle cell number, the
association did not reach statistical significance. The results did not
materially change when correcting for antithrombotic medication,
lipid-lowering drugs, and smoking status. Also, expression quanti-
tative trait locus (eQTL) analysis revealed no association between
M1(A213) and AAT levels in atherosclerotic plaques.
M1(V213) Has a Higher Dissociation Constant Toward NE than
M1(A213). To explore potential functional differences between
M1(A213) and M1(V213) with respect to their inhibitory be-
havior, we analyzed the initial interaction between AAT and NE.
We characterized the formation of the encounter complex under
equilibrium conditions using fluorescently labeled and catalyti-
cally inactive NE (S195A variant) in a microscale thermopho-
resis assay (25). AAT-deficient plasma [1:12 dilution in PBS
(vol/vol)] was used as a matrix to include plasma-specific inter-
actions that may influence the encounter complex formation
between AAT and NE. Under this condition, the M1(A213)
variant [dissociation constant (KD) = 3,200 ± 500 nM] exhibited
an almost twofold lower dissociation constant than the M1(V213)
variant (KD = 6,800 ± 1,000 nM) toward NE (Fig. 3A). These allele-
specific differences disappeared when AAT-deficient plasma
was freed from lipoproteins by ultracentrifugation and dialyzed
against a phosphate buffer over a membrane with a 10-kDa
cutoff (Fig. 3B).
M1(A213) Enhances the Structural Flexibility of AAT. To determine the
impact of the two variants on AAT structure, we further de-
termined the hydrogen/deuterium exchange rates for M1(V213)
and M1(A213). As illustrated in Fig. 4, the exchange rates be-
tween the two variants significantly differed for multiple pepsin-
generated peptides. In several surface regions, the M1(A213)
variant was more susceptible to deuterium uptake by one to three
ions per fragment compared with M1(V213). Of note, significant
differences in the deuterium uptake were also observed at a dis-
tance from residue 213. Specifically, the Ala-213 substitution led
to a higher flexibility of the C-terminal end of the reactive center
loop, including strand 1 of the C β-sheet (s1c) as well as strand
5 of the A-sheet in the shutter region (s5A) (26) (Fig. 4). Con-
ceivably, the increased dynamics of the Ala-213 variant may
reduce exosite interactions with other plasma components, and
may thus account for the observed higher affinity for NE in the
complex plasma environment.
Discussion
Our study enabled us to detect the common variants with a
moderate effect size that are associated with LAS (90% power to
detect variants with >5% MAF and OR > 1.2), although the
power to detect rare variants was limited. The results obtained
for HDAC9, MMP12, and CYP17A1 are consistent with previous
studies (4, 11, 21, 22) that have shown associations between LAS
and common variants in these regions within noncoding DNA.
The variant rs2023938, which reached exome-wide significance
in the current study, is located in the 3′-UTR of HDAC9 and is in
high LD with rs2107595 and other variants previously shown to
be associated with LAS (4, 11). The variant rs2107595 resides in
regulatory DNA, and the risk allele of this variant has previously
been shown to associate with elevated expression levels of
HDAC9 (27). Genetic ablation of HDAC9 attenuates athero-
progression in atherosclerosis-prone mice (27, 28). Hence, the
effects of this locus seem to be mediated by altered HDAC9
expression levels.
Table 1. Top association signals from the exome chip analysis
dbSNP ID no. Chromosome:position Minor/major allele MAF Functional annotation Gene P value OR [CI_95]
Common variants
rs6647 14:94847415 G/A 0.18 p.Val237Ala SERPINA1 5.99E-9 1.22 [1.13–1.31]
rs2023938 7:19036775 G/A 0.09 3′-UTR HDAC9 7.76E-7 1.28 [1.16–1.40]
rs11553746 2:272203 T/C 0.35 p.Thr95Ile ACP1 3.67E-6 1.14 [1.07–1.21]
rs11681377 2:65394714 T/C 0.47 Intergenic Intergenic 5.91E-6 1.15 [1.08–1.22]
rs2290911 2:224919 G/A 0.34 Synonymous SH3YL1 5.65E-6 1.14 [1.07–1.21]
rs10863936 1:212237798 G/A 0.49 Intronic DTL 7.33E-6 1.19 [1.12–1.26]
rs11191447 10:104652323 T/C 0.09 Intronic C10orf32-AS3MT 1.18E-5 1.22 [1.10–1.36]
rs1004467 10:104594507 C/T 0.10 Intronic CYP17A1 3.22E-5 1.20 [1.08–1.32]
rs17368582 11:102738075 C/T 0.13 Synonymous MMP12 3.30E-5 1.20 [1.10–1.31]
rs1172822 19:55819845 T/C 0.36 Intronic BRSK1 3.69E-5 1.19 [1.10–1.28]
rs11191580 10:104906211 C/T 0.09 5′-UTR NT5C2 5.70E-5 1.21 [1.09–1.35]
Low-frequency variants
rs62019510 15:85657120 G/A 0.03 p.Asn329Ile PDE8A 5.60E-5 1.39 [1.18–1.63]
rs111986709 18:29054294 T/C 0.04 p.Ser771Tyr DSG3 6.08E-5 1.35 [1.17–1.57]
rs2231400 9:135753629 G/A 0.04 p.Ile5Thr AK8 7.77E-5 1.30 [1.12–1.50]
Rare variants
rs45439291 22:41077613 A/G 0.003 p.Arg191Gln MCHR1 9.99E-7 2.08 [1.34–3.24]
rs114895119 9:139264888 A/T 0.003 p.Glu270Val CARD9 3.81E-6 1.84 [1.41–2.40]
Shown are the results from the single-variant analysis for common, low-frequency, and rare variants with a P value <1E-4. P values and ORs are displayed
from the transethnic metaanalysis of the German, UK/Australian, and South Asian samples. SNP position and functional annotation are given for hg19.
Exome-wide significant results are shown in bold. dbSNP, the single nucleotide polymorphism database.
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The primary finding of this study is an association of the
common M1(A213) variant of AAT with LAS. This variant has
not previously been identified through regular genome-wide as-
sociation study (GWAS) approaches, and it constitutes a po-
tential novel risk factor for LAS. No other variant within or near
AAT showed a significant association with LAS. Several factors
might explain why this association was not identified by previ-
ous GWAS approaches: (i) variations in the accuracy of pheno-
typing across studies and, hence, reduced statistical power (29);
(ii) variations in imputation accuracy; and (iii) differences in allele
frequencies for M1(A213) within the European superpopulation
(14) and different regional compositions of previous GWAS
discovery cohorts.
A role of SERPINA1 in atherosclerosis is further supported by
a recent study that found sixfold higher expression levels of
SERPINA1 in human atherosclerotic lesions compared with
healthy arteries (30). The target enzyme of AAT, NE, is expressed
by macrophages in human atherosclerotic plaques (17), particularly
within advanced atherosclerotic lesions (31). AAT might facilitate
protection against matrix breakdown by NE and clearance of lipo-
protein deposits. However, the issues of whether AAT is protective
against atherosclerosis and whether AAT levels correlate with the
progression of vascular disease are still debated (16, 32–34).
The observed association between rs6647 and LAS is unlikely
to be mediated by differences in AAT levels. First, previous
studies have shown similar concentrations of circulating total
AAT among carriers of the M1(A213) and M1(V213) alleles (16,
19, 20). Second, we found no differences in the frequency of the
Z and S alleles between cases and controls. Third, the associa-
tion between rs6647 and LAS remained stable when removing
carriers of a Z or S allele from our cohorts (35). Finally, eQTL
analysis in the Athero-Express data showed no eQTL of M1
(A213).
Previous functional studies found no difference in the in-
hibitory capacity and association rate constants between the two
most frequent M1 AAT variants in Caucasians (20). However,
these studies were performed with purified proteins in simple
protein- and lipid-free buffer systems. In contrast, the microscale
thermophoresis method applied here disclosed a clear difference
between the two variants. This method accounts for all interac-
tions of AAT with components of the plasma matrix, which can
modify the strength of interactions between AAT and NE, as we
recently showed for the AAT-Z variant (36). Under these con-
ditions, the dissociation constant between the enzymatically in-
active NE and AAT was found to be lower for M1(V213) than
for M1(A213), indicating that components of the plasma matrix
interfered more strongly with the former allele. The dimorphic
residue at position 213 is located in the loop between strands 3
and 4 of the C sheet (s3C and s4C) and is exposed to the surface.
The exposed position and hydrophobic nature of this turn make
it suited for hydrophobic interactions with major plasma pro-
teins, particularly lipoprotein particles. Compared with Val-213,
the Ala-213 residue displays lower hydrophobicity and side-chain
entropy, which reduces the extent of hydrophobic interactions by
the s3C-s4C connecting turn of M1(A213).
Apart from the obvious single-residue substitution, further
differences of the global structure were noticed in several surface
regions at a distance from position 213. The subtle change in
global structural flexibility between the two variants evidently
does not influence the interaction between AAT and catalytically
inactive NE in lipid-free plasma. This finding is consistent with
earlier studies that used simple buffer systems (20). However, the
lower hydrophobicity of the Ala-213 side chain and the higher
surface entropy of the M1(A213) variant most likely reduce
its interactions with plasma lipoproteins compared with the
M1(V213) variant.
Recent studies have provided evidence for an interaction be-
tween AAT and lipoproteins, including both LDL (37) and HDL
(38, 39). Binding of AAT to reconstituted HDL reduced the
inhibitory capacity of AAT toward NE (39), and a similar effect
was seen in our study when lipoproteins were removed from the
plasma matrix. Moreover, we noticed that allele-specific differ-
ences of the dissociation constant disappeared, supporting our
hypothesis of an altered interaction of M1(V213) AAT with li-
poproteins in the complex plasma environment.
Better binding to lipoproteins could improve the local avail-
ability of the functional Val-213 inhibitor in atherosclerotic
plaques. Moreover, we suggest that the more dynamic flexible
state of the Ala-213 variant increases the likelihood of proteolytic
inactivation by other proteases, particularly metalloproteases
(MMP12), in atherosclerotic lesions. The precise molecular
mechanism by which the M1(V213) variant reduces the risk of
LAS, however, remains to be determined.
Primate sequences, including sequences of archaic hominids,
indicate that the M1(V213) change, which does not occur in
other mammals, arose in Africa before the divergence of modern
humans (40, 41). In contemporary populations, M1(V213) is
least frequent in Africa, more frequent in Europe, and almost
fixed in East Asians and Native Americans. Whether this dif-
ference in allele frequencies relates to differences in LAS risk
across different populations remains to be determined.
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Fig. 3. Functional differences between M1 AAT variants found in lipid-
containing, but not lipid-free, plasma. Shown are the fitted binding curves
of the microscale thermophoresis assay under equilibrium conditions in lipid-
containing (A) and lipid-free (B) plasma. A fixed concentration of fluo-
rescently labeled and catalytically inactive NE was titrated with the M1(A213)
or M1(V213) variant in AAT-deficient plasma. (A) In the presence of lipids,
the KD (KD) observed with theM1(V213) variant [KD(A213) = 6,800 ± 1000 nM]
was substantially higher than the KD observed with the M1(A213) variant
[KD(V213) = 3,200 ± 500 nM]. (B) In the absence of lipids, there was no
discernible difference between the two variants [KD(A213) = 540 ± 50 nM;
KD(V213) = 550 ± 60 nM]. Fitted binding curves and KD values (mean ± SD)
were derived from global fitting of three measurements (three independent
protein expressions). The measurements were performed in 7.5% plasma
and with 5 nM labeled NE.
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Materials and Methods
Study Participants, Genotyping, and QC. We studied 3,202 participants with
LAS involved in the following cross-sectional stroke studies: (i) German
samples from Munich and the Westphalian Stroke Registry; (ii) UK samples
from London, Edinburgh, and Oxford, including samples from the Wellcome
Trust Case Control Consortium 2; (iii) Australian samples from the Australian
Stroke Genetics Consortium study; and (iv) South Asian samples from the
Risk Assessment of Cerebrovascular Events study (Pakistan). LAS was defined
according to the Trial of Org 10172 in Acute Stroke Treatment classification,
with radiological confirmation of stroke subtype. A total of 9,862 stroke-free
control samples were selected from the Kooperative Gesundheitsforschung
in der Region Augsburg S4/F4 study to match the German sample, from the
1958 Birth Cohort/Wellcome Trust Case Control Consortium 2 to match the
UK and Australian sample, and from the Pakistan Risk of Myocardial Infarction
study to match the South Asian sample (Table S1 and SI Materials and Methods).
The relevant institutional review boards and ethics committees of participating
institutions (medical faculty of Ludwig Maximilians University, John Hunter
Hospital, Queen Elizabeth Hospital, Royal Perth Hospital, St. George’s Hospital,
University of Oxford, University of Edinburgh, and University of Münster) ap-
proved these studies, and written or oral consent was obtained from all partic-
ipants. Genotyping of cases and controls was done using the Illumina
HumanExome-12v1 or HumanExome-12v2 Beadchip, holding information on
more than 240,000 functional exonic variants. Further information on the gen-
otyping, QC, and statistical analysis can be found in SI Materials and Methods. In
total, 75 cases and 84 controls were removed after QC, resulting in 3,127 cases
and 9,778 controls being included in the final analysis.
Statistical Analysis. Single-variant association analysis was conducted using
PLINK (42) by logistic regression adjusted for the first two principal com-
ponents using genomic control to correct for population genetic sub-
structure. Common variants (MAF > 5%; n = 26,543), low-frequency variants
(1% < MAF < 5%; n = 7,042) and rare variants (MAF < 1%; n = 59,187) were
studied separately, setting Bonferroni-corrected P-value cutoffs at P < 1.88E-6,
P < 7.10E-6, and P < 8.45E-7, respectively. Metaanalysis was performed using
fixed-effects models based on inverse variance-weighted effect size for the
German and UK/Australian cohorts. Han and Eskin’s (43) random effects
model optimized to detect associations under heterogeneity was used for
the transethnic metaanalysis. Effects of nonsynonymous variants were
checked by PolyPhen2 (44), SIFT (45), and PROVEAN (46). The significance
level of gene-based association tests was set at P < 2.91E-6 (accounts for
Bonferroni correction for the number of genes).
Determination of the Dissociation Constants. Information about expression
and purification of recombinant proteins, labeling of NE, and determination
of the concentration of recombinant AAT is provided in SI Materials
and Methods.
Before each experiment, all protein stocks and plasma samples were
centrifuged for 5 min at 20,000 × g at 4 °C. Plasma and fluorescently labeled
catalytically inactive elastase were mixed in buffer 1 [20 mM Na2HPO4,
300 mM NaCl (pH 7.4)] and 0.02% Tween-20. Antiphotobleaching enzyme
and substrate components were added according to the manufacturer’s
protocol (Monolith Anti Photobleach Kit; NanoTemper Technologies). A di-
lution series of both AAT variants in buffer 1 was prepared. The AAT dilu-
tions were then mixed with buffer 1 at a volume ratio of 1:1, yielding a final
concentration of 7.5% (vol/vol) AAT-deficient plasma and 4.5 nM elastase.
The relatively high background of blood plasma necessitates a background
subtraction. The background mixture includes everything but labeled elastase
and AAT. The samples were incubated at 22 °C for 2 h. Samples were measured
in NT.115 MST Premium-coated capillaries (NanoTemper Technologies) on a
Monolith NT.115 Pico instrument (NanoTemper Technologies) at 22 °C using
10% light-emitting diode and 40% infrared (IR) laser powers with IR laser on/off
times of 20/5 s. Each dilution point was measured in triplicate. For each plasma
sample, the whole procedure was performed three times to yield independent
triplicates. After subtracting the background, the relative fluorescence depletion
values were normalized to the saturation value, at which value all molecules
were in the bound state. Normalized depletion values corresponding to the
fraction of bound elastase molecules of three technical replicates were plotted
on a linear y axis against the concentration of the serially diluted AAT on the
log10 x axis, resulting in binding curves. In Igor Pro-5.03, a global fit of at least
three replicates to the quadratic solution of the mass action law was performed
to yield the dissociation constant of each curve with a weighted error fit (further
details are provided in SI Materials and Methods).
Hydrogen/Deuterium Exchange Measurements Using Mass Spectrometry.
Deuterium/hydrogen exchange and quantification were performed as pre-
viously described (47). In brief, exchange reactions were initiated by diluting
5 μL of 25 μM AAT with 45 μL of D2O containing buffer, and the reaction was
stopped at different time points (10 s, 1 min, 10 min, 60 min, and 120 min) by
further addition of 50 μL of quench buffer (100 mM phosphate buffer, pH 2.5).
The quench reactions were immediately injected in a Waters HDX system with
in-line pepsin digestion. The peptides were separated on a C18 column before
analysis on a Waters Synapt G2 mass spectrometer. The back-exchange re-
action of hydrogens was corrected using a fully deuterated sample that was
obtained by incubating AAT in D2O containing high-concentration deuterated
guanidine DCl before quenching. At all time points, undeuterated and fully
deuterated controls were analyzed in triplicate. Peptide identification was
performed with the ProteinLynx Global Server. Coverage maps and deuterium
uptake for each peptide was obtained with DynamX 3.0.
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